Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Year: 2021
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Institutions: Dana-Farber Cancer Institute, Sungkyunkwan University, Hospital Universitario HM Sanchinarro, National Taiwan University Hospital, Tennessee Oncology, Seagen (United States), Centre Léon Bérard, Azienda Ospedaliero-Universitaria di Modena, IRCCS Ospedale San Raffaele, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Novartis (United States), National University Cancer Institute, Singapore, National University Hospital, National University Health System
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ribociclib, fulvestrant, hormone receptor-positive HER2-negative breast cancer, advanced breast cancer, CDK4/6 inhibitors, PI3K inhibitors, alpelisib, buparlisib, endocrine therapy resistance, triple combination therapy, recommended phase 2 dose, drug safety and tolerability, drug-drug interactions, pharmacokinetics
Open Access status: closed
OpenAlex ID: W3083026664
